S
Sridevi Devaraj
Researcher at Baylor College of Medicine
Publications - 390
Citations - 23771
Sridevi Devaraj is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Metabolic syndrome & Proinflammatory cytokine. The author has an hindex of 85, co-authored 365 publications receiving 21831 citations. Previous affiliations of Sridevi Devaraj include University of Madras & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo.
Joy X. Jiang,Xiangling Chen,Nobuko Serizawa,Cedric Szyndralewiez,Patrick Page,Katrin Schröder,Ralf P. Brandes,Sridevi Devaraj,Natalie J. Török +8 more
TL;DR: GKT137831 is a potent inhibitor of fibrosis and hepatocyte apoptosis and a promising therapeutic agent for future translational studies, and plays a key role in liver fibrosis.
Journal ArticleDOI
Toll-like Receptor Status in Obesity and Metabolic Syndrome: A Translational Perspective
TL;DR: Evidence is presented for a pivotal role of TLR-induced inflammation in both obesity and MetS and it is speculated that targeting these TLRs can forestall their adverse sequelae of diabetes and cardiovascular disease.
Journal ArticleDOI
The Evolving Role of C-Reactive Protein in Atherothrombosis
TL;DR: CRP is clearly a risk marker for cardiovascular disease and is recommended for use in primary prevention and appears also to contribute to atherogenesis, however, much further research is needed.
Journal ArticleDOI
Hyperglycemia Induces Monocytic Release of Interleukin-6 via Induction of Protein Kinase C-α and -β
TL;DR: The aim of this study was to examine molecular mechanisms for increased IL-6 release from monocytes under hyperglycemia in type 2 diabetic patients and found secreted IL- 6, intracellularIL-6, and IL-8 mRNA were significantly increased with hyperglyCEmia.
Journal ArticleDOI
Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome.
TL;DR: The combination of AT and GT supplementation appears to be superior to either supplementation alone on biomarkers of oxidative stress and inflammation and needs to be tested in prospective clinical trials to elucidate its utility in CVD prevention.